摘要:
New protein-polycation conjugates are capable of forming soluble complexes with nucleic acids or nucleic acid analogs. The protein portion of these conjugates is a protein capable of linking with a cellular surface protein expressed by cells of the T-cell lineage, so that the complexes thus obtained are absorbed by cells which express the T-cell surface protein. Complexes useful in pharmaceutical compositions contain a therapeutically or gene therapeutically active nucleic acid.
摘要:
De nouveaux conjugués de protéines et de polycations capables de former avec des acides nucléiques des complexes solubles contiennent en tant que portion protéinique un anticorps dirigé contre une protéine de la surface cellulaire capable de se lier à la protéine de la surface cellulaire, de sorte que le complexe ainsi formé soit absorbé par les cellules qui expriment la protéine de surface cellulaire et soit exprimé dans celles-ci. Ces complexes utiles dans des compositions pharmaceutiques contiennent un acide nucléique thérapeutique ou actif en thérapie génétique.
摘要:
Recombinant CELO virus or CELO virus DNA with a deletion at the right end of the viral genome that allows insertion of large pieces of foreign DNA. The virus is useful as a vaccine for animals, in particular birds, and for gene therapy and vaccine applications in humans. The virus can also be used for recombinant protein production.
摘要:
Novel protein polycation conjugates which are capable of forming soluble complexes with nucleic acids contain as the protein component an antibody aimed at a cell surface protein with the ability to bond to the cell surface protein so that the complex formed is absorbed into the cells expressing the cell surface protein and expressed therein. Complexes for use in pharmaceutical preparations contain a therapeutic or genetherapeutic active nucleic acid.
摘要:
The invention relates to a chicken embryo lethal orphan (CELO) virus obtained by in vitro manipulation of plasmid-cloned CELO virus DNA. Said virus is suitable for production of vectors for gene therapy and as a vaccine against infectious diseases in humans and animals, in particular birds.
摘要:
The toxicity problems arising when foreign matter is introduced into higher eukaryotic cells, especially with transfection with DNA, are obviated by expression in the cell of gene products that block the apoptosis induced by the transfection process and/or by treating the cells with anti-inflammatory substances. Preferred anti-apoptosis genes are Bcl-2, E1B 19K or an anti-apoptotic gene of the CELO avian adenovirus; used as preferred anti-inflammatory substance in the adenovirus VA1, which is introduced into the cell in the form of VA1 DNA. These measures help to achieve a long-lasting gene expression.
摘要:
Complexes between internalisation factor-binding factor conjugates and nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis contain, in non-covalently bonded form, one or more substances with an affinity for nucleic acid with the ability to increase the efficiency of the absorption of the complexes into the cell. The non-covalently bonded substance with an affinity for nucleic acid may be the same as the binding factor, and preferably a polycationic substance. The preferred internalisation factor is transferrin. Process for producing the complexes and process for introducing nucleic acid into higher eucaryotic cells. Pharmaceutical preparations containing complexes with a therapeutically active nucleic acid.
摘要:
On peut utiliser de nouveaux conjugués, dans lesquels la liaison entre une glycoprotéine et une substance liant des acides nucléiques est assurée par la partie glucidique de la glycoprotéine, afin d'importer des acides nucléiques utiles en thérapie ou en thérapie génétique dans des cellules qui expriment à leur surface une protéine à laquelle la glycoprotéine se lie. La glycoprotéine est de préférence la tansférine et la substance liant des acides nucléiques est de préférence un polypeptide polycationique homologue, tel la polylysine. On peut produire ces conjugués en oxydant le groupe glucidique de la glycoprotéine, notamment l'acide sialique, jusqu'à obtenir sa forme aldéhyde, et en le couplant à la substance liant des acides nucléiques, qui comprend de préférence des groupes amino. Des complexes contenant ces conjugués et un acide nucléique efficace font partie de compositions pharmaceutiques utiles en thérapie ou en thérapie génétique.